good you, today. you Thank and morning, for Jeremy, Thank everyone. joining us
extremely like we today. will and COVID-XX, with are, our crisis the the on the world, that everybody of spread caused concerned certainly We around humanitarian by and economic thoughts provide
our working we to plastic with and and are patients, the our we families, communication help we employees can. worldwide foremost, and constant their to however surgeons of in First protect health our are and partners
and that strength discuss economy take finished The to XXXX world as XXXX. which is industry grapple the strong are with we our adapt the While business our global we it taking challenge. the of we COVID-XX, actions with through make and and manage in can still this to important the effects fundamentals
fiscal by year discussing us XXXX. our start Let
$XX.X was XX.X% of period During the XXXX, same XXXX. the million, revenue of over of an fourth quarter increase
XX.X% year, are high-end over quarter revenue we the of results of Motiva is XXXX. XX. an record of by full-year made on increase announced adoption revenue in the the possible release a For the continued it preliminary another And ranges These Implants. was financial $XX.X press a January global million, towards
guidance full-year given is an are like Issuing and a planning going enough formal guidance impossible environment rapidly we last a to were we high formal task developing to a world with for the events, growth today. of ours company to normal story COVID-XX. issue but forego XXXX, challenging providing Prior week, for novel in guidance
visibility XXXX results. best help of that we this anticipate we like significant to and Please shareholders remember our To And from to $XX revenue would have to in quarter our million based give the our on our in think as $XX a we that today of some into million. COVID-XX we be about range information today, impact the March. is year, in to have business first factor
formal issue call environment first currently to time. May, normalized more a quarter at guidance we Assuming intend for that in
are have those in we to surgeries government. I'm speaking are not tourism, there surgeons Chinese long members, restrictions available our expect all as indicated surgeries place with have of no medical Motiva example, those schedule team Korea, of in they having as as to surgeons patients do portion China as seeing patients and by commercial daily, that operate Surgeons date, are continue however, in and that their a market most impacted. surgeries come does be South would performed. for is plastic the To from some slowing,
fact that obviously and a the of Italy COVID-XX Europe, the will grapple under countries XX%, impact get to the COVID-XX. more. regions world our in approximately revenue restrictions are as as than spread the to East, virus Middle will number increasing need control, we of of such The times as responds more XX% significant important to that year. an revenue If is of countries our XX mandate protection of very nature XX% with The different provide at worst Latin diverse this likely to Asia-Pacific different some America level should business
on are as above, course, primary we chain. mentioned aspects of any Of I reliant not China supply our for
of about experience industry. As can tell breast our implant has team you business, our I we in forecasting think that executive the decades
One capabilities are Disability taken position with Sweden, that Motiva situations agile environments. of diverse and dealing has Colombia is have markets and such South experience Korea. organization and the is reason commanding core of such we our changing Implants as deep in the adaptable company that a
or Further, of these experience opt the If But woman cancel their team extensive, once has an their well women a through thoughtful aesthetics interested process. very reschedule following: surgery taught breast most in our has surgery. collective they develops, deliberate procedure, management they situation have may put and will their as situation that to go resolved. an us ultimately had extraneous and
been when a economic sustained and negative significant has has been downturns, news headlines there true during implant has previous the been not severe only industry. about it This true breast even
before be experienced maintain that As trajectory positioned pandemic situation resolves, currently we that this the we to believe this started. will we growth
which and growth been advertising, our online marketing multifaceted to physician media and a strategy, patient social engagement, education. has initiatives includes One employ of
our to plastic supporting, a communicating of We are our and taking this with as patients. mean digital and training opportunity communication surgeons media channels optimize
very are of these to When pleased offering in managing million cash also completed public this $XX January. a a us all uncertainties. are We given gives position. This healthy carefully, have we very
million of fourth During million the for $X.X $XX.X XXXX, quarter XXXX fund of quarter $X and quarter operations million third to the we used compared for fourth of the to XXXX.
review access manage reallocate path we cash future with our done this as levers number to expenditures. a We breakeven able to lower on our positive. continues We to cash continue into the to can in pandemic or well have of flow develop, our business to the and full budget, are XXXX a of reduce, suspend burn
Most have our significant market our reputation and fundamentals in business of the the importantly, remain momentum. product, underlying and strong brand
healthy very have We necessary this margins, of to out gross take in are and we period come in a position than stronger steps our cash healthy industry. to the a others position,
our specific to QX the now drivers Turning of performance.
increased ergonomics share average market with prices. was have again Our along higher the driven growth which balanced regions by of our all generally selling sales world, of across stronger implants,
and Colombia and France markets our and direct Australia strength Specifically, showed in Germany markets. our in outperform distributor
to single our drive region strength We regions to of this a not the continued different beholden continue world to see are across and the success.
our impact and revenue for revenue to accounted to total sales Direct positively of force fourth market the for Brazil total our continued market revenue our Europe Brazil third performance. quarter. The launch of XX% direct in strongest our the quarter the compared was XX% across XXXX. as of for
Brazil total testament global XX.X% meaning success This our the commercial with second execution for aesthetics. that investments breast year-over-year, For the a generated consistent full-year, was over to market the largest in revenue. Brazil XXXX, grew XX% of of our in
QX in Taiwan previously markets latter of XXXX. of we one as strong in and Additionally, into Thailand, aesthetic were announced, QX largest were distributor the being two These and markets Asia. markets our last the with new year
pandemic. Although the we in light continue ongoing in of monitor to closely Asia developments
XXXX. XX.X% our were in the is of fourth a the fourth margins revenues over revenues, of Gross was for full the revenues, of revenues full-year quarter Improvements XXXX. for quarter to and of which quarter margins another compared full-year in were improvement significant of XXXX of margins highlight Gross XXXX XX.X% gross for the fourth XX% results. XX.X%
in a key is part global standard Geographic expansion long-term to of work strategy growth as aesthetics. breast we become the our
While have for of our addressable than growth are a growth China significant opportunity noting the and organic countries which our into we market, to more we be significant is total U.S. currently it worth commercially XX in that expect available. Motiva by drivers Implants long-term tripling
and patients. products in the to continue efforts talk of share key continuing market patient practices about Plastic improved their one our to gains patients are is surgeons reach and potential surgeons drivers preference our our the our to outcomes. directly and out as of safety Patient we benefits of both adopt
quarter, with quarterly. safety of less During post-market surveillance, events which related our complication for the this end we milestone Notably, in was the achieved Implant X Motiva the very significant published we than X% in only rate and years announced fourth millionth market. XX
Capsular A peer of double are and implants. with implant the late reported capsule retrospective reviewed implant complication rupture Implants, for seromas. related cases failure device of and no two capsules breast patients no of cases contracture associated most at rates Motiva and rupture. X,XXX SmoothSilk common X reported study reasons years no contracture, of X.XX% No with to up
the of publications unique proof to We clinical Motiva and scientific Implants. see evidence are papers with happy profile safety of in peer reviewed more
outcomes and since our published on papers behind alone, in observed confirmation we that we the in have technology XXXX. Implants, Just XX clinical science surveillance post-market our of saw XXXX Motiva further the quarterly
in papers patient driving interest more in the are market complications. basis on feedback is our to of these including gains. products relative safety the force scientific surgeon products, characteristics a papers safety we growth the expect believe substantially on adoption related of implant a experience, profile in technology and our Hands-on share Motiva creating result unique why and We in groundswell of market its other our to publications and behind continued of published be additional reduced XXXX,
approval current of product expansion offerings continue new products. several efforts geographic regulatory the and a Our to progress towards our path with for
have implants We on the comprehensive offerings. of smooth build these worldwide and to continuing portfolio most are
are submission expander portfolio. adoption expander in meaningful registration the in represents submissions market These our and announced our the our expanders CE important addition SmoothSilk the and reconstruction design to advanced all We our tissue fuel breast for a products. XXX(k) company The tissue EU. milestone for previously Mark should tissue of U.S in for product of the a
work as to strategy. respective launch to process approval regulatory the continue We finalize bodies with we the our through work
MRI expander a for our is it reminder, substantial tissue SmoothSilk plastic and women's the difference with a no have that proprietary health. a make of a we'll magnets, the surface the is can the substantial with surgeons includes patients, tissue as integrated and oncologists, expander use industry alongside enabling our impact is As scanning. real and This port only innovation on safely an advance real expanders to
believe Turning addressable that cases December. last medical introduction specialties, potential the minimally Mia, to initiative bringing the has for we invasive a to other augmentation total to market aesthetics. market breast in in we surgeries breast grow Asia Motiva breast augmentation began invasive minimally minimally of to worldwide our Similar for the invasive
are smooth plastic beginning we complete. the a For global to transition community, will to take to which surgeon time some see implants,
different to have the surgical implants other techniques transitioning and involve does some smooth responsibly and education. from Textured one
another medical further scientific technology. to our with surgeons patients this opportunity taken and transition We provide surface have details and about ongoing as both industry, our education
to transition surface the As implants specifically, we believe our smooth provide considerable world, education proprietary around the with will SmoothSilk Implants and medical accelerate. more we Motiva
also growing from are We patent the differentiate that and to unique are others innovations technology. application we a year, the dedicated property surface Last portfolio in us protecting announced our key implant our Patent market. allowed Office covering U.S. that the intellectual
today issue few patent the We office announce are that pleased will within weeks. patent a to that
to developing with protect that will to innovations We outcomes IP dedicate innovations a patient and those continue robust resources improve portfolio.
U.S Turning trial. now clinical our to
in during to FDA IDE cohort, we the In the trial of of reconstruction continue the all and progressing are the Implants. clinical August We announced our progress we quarter surgeries last cohort. for pivotal in advancing completion fourth year, make Motiva aesthetic
strategy large for submission part in the timelines we U.S. our to discussed that FDA PMA last our bifurcation quarter. due on remain to the Importantly, track
primary the our revision submission FDA necessary take for cohorts, and submission of the that light pursue steps this we with process. indications this the to we complete the give to communications continue bifurcation the aesthetic us the were augmentation we reconstruction In able ahead in to further in intend confidence augmentation fact Recent of indications. for strategy
to call Renee the I'd Renee? in detail. the financials discuss that, turn to With like over to
